recombin
felin
interferonomega
rfeifnx
virbagen
omega
virbac
immunemodul
drug
licens
use
europ
australia
asian
countri
among
main
therapeut
indic
frequent
use
manag
felin
immunodefici
viru
fiv
felin
leukemia
viru
lutz
et
al
rfeifnx
therapi
induc
clinic
improv
retrovir
infect
cat
de
mari
et
al
domenech
et
al
gil
et
al
increas
surviv
time
de
mari
et
al
slightli
chang
clinic
paramet
hypergammaglobulinemia
ratio
provir
load
viremia
previous
report
retrovir
infect
cat
rfeifnx
therapi
domenech
et
al
accord
author
rfeifnx
thought
act
innat
immun
domenech
et
al
recent
anoth
studi
report
rfeifnx
licens
protocol
improv
clinic
present
reduc
concurr
viral
excret
natur
retroviralinfect
cat
live
catteri
suggest
use
multicat
environ
viralrel
disord
often
clinic
problem
gil
et
al
studi
signific
abnorm
observ
hematolog
biochemistri
profil
treatment
gil
et
al
rfeifnx
licens
protocol
consist
therapeut
cycl
daili
subcutan
inject
mukgday
begin
respect
day
protocol
expens
cost
may
limit
frequent
use
bypass
problem
altern
protocol
oral
one
suggest
altern
use
rfeifnx
certain
situat
addi
bracklein
et
al
hennet
et
al
author
previous
describ
increas
express
mx
protein
specif
biomark
ifninduc
antivir
respons
specificpathogenfre
cat
treat
oral
variou
concentr
rfeifnx
bracklein
et
al
studi
shown
higher
oral
dose
rfeifnx
induc
higher
level
mx
protein
express
confirm
activ
oral
protocol
bracklein
et
al
anoth
recent
studi
report
success
use
random
doubleblind
studi
calicivirusposit
retroviru
neg
cat
caudal
stomat
hennet
et
al
protocol
consist
daili
oromucos
rfeifnx
administr
mucat
day
associ
signific
clinic
improv
lesion
author
describ
use
noneffus
form
felin
infecti
periton
fip
ucat
po
daili
addi
nevertheless
benefici
effect
rfeifnx
manag
fip
still
fulli
establish
ishida
et
al
ritz
et
al
date
littl
known
clinic
benefit
rfeifnx
via
oral
rout
cat
retrovir
infect
similarli
observ
human
interferonalpha
hifna
therapi
daili
oral
administr
rfeifnx
may
provid
effect
immun
modul
fiv
cat
author
knowledg
one
trial
perform
use
experiment
infect
asymptomat
fiv
cat
caney
et
al
describ
success
use
daili
oral
rfeifnx
dose
mucat
week
intend
assess
clinic
benefit
although
signific
chang
obtain
proviru
load
ratio
anim
increas
bodyweight
oral
protocol
well
toler
caney
et
al
howev
studi
perform
order
evalu
whether
oral
administr
rfeifnx
effici
cat
natur
occur
retrovir
infect
use
longer
period
symptomat
cat
daili
practic
clinic
paramet
permit
direct
indirect
assess
immunestimul
induc
rfeifnx
among
serum
protein
electrophoresi
spe
acut
phase
protein
app
potenti
complementari
exam
evalu
immun
system
treat
cat
spe
laboratori
test
allow
separ
serum
protein
base
size
electr
charg
serum
protein
therefor
divid
differ
fraction
alpha
beta
gammaglobulin
whose
increas
decreas
interrel
taylor
et
al
gammaglobulin
fraction
special
relev
fiv
cat
increas
fraction
associ
chronic
antigen
stimul
accord
previou
studi
tend
occur
fiv
posit
cat
gleich
hartmann
mainli
due
concurr
infect
polyclon
bcell
activ
direct
consequ
fiv
infect
seen
even
appar
healthi
fivposit
cat
ackley
et
al
flynn
et
al
gleich
hartmann
hartmann
human
medicin
especi
low
resourc
area
spe
use
monitor
respons
antiretrovir
therapi
hiv
patient
sarro
et
al
therefor
spe
could
promis
complementari
exam
fiv
infect
cat
app
recent
measur
variou
felin
diseas
paltrinieri
seem
modul
innat
immun
respons
reinforc
bodi
defens
inflamm
ceron
et
al
paltrinieri
petersen
et
al
henc
app
serum
level
seem
indirect
indic
innat
immun
system
stimul
recent
studi
describ
use
app
level
monitor
effect
licens
rfeifnx
protocol
innat
immun
fivposit
cat
treat
cat
increas
agp
serum
amyloid
saa
creactiv
protein
crp
suggest
paramet
may
reliabl
individu
monitor
rfeifnx
immunemodul
therapi
leal
et
al
present
studi
aim
evalu
clinic
improv
laboratori
find
cbc
biochemistri
spe
concurr
viral
excret
acut
phase
protein
agp
saa
crp
natur
fivinfect
cat
treat
oral
rfeifnx
protocol
comparison
licens
one
anim
treatment
protocol
fivposit
cat
treat
oral
rfeifnx
po
group
result
compar
data
previous
obtain
fivposit
cat
treat
licens
protocol
sc
group
inclus
criteria
use
base
previou
public
de
mari
et
al
gil
et
al
medic
apart
rfeifnx
allow
period
studi
retrovir
statu
confirm
anim
elisa
kit
use
serum
plasma
sampl
viracheckfiv
viracheckfelv
synbiot
result
sc
group
previous
publish
singlearm
trial
evalu
clinic
improv
concurr
viral
excret
gil
et
al
data
group
consid
posit
control
current
studi
po
group
consist
natur
fivinfect
cat
refer
veterinari
teach
hospit
treat
obtain
owner
consent
mucat
rfeifnx
oral
day
consecut
day
cat
singleh
live
indoor
one
cat
cat
outdoor
anim
came
multicat
environ
obtain
correct
dose
vial
contain
rfeifnx
freezedri
pellet
mu
dilut
ml
steril
physiolog
salin
singledos
prepar
use
ml
syring
contain
ml
one
member
research
group
given
owner
instruct
administ
therapi
syring
kept
frozen
prepar
owner
defrost
singl
dose
shortli
administr
anim
submit
full
clinic
evalu
day
therapi
anim
po
group
addit
evalu
day
end
therapi
studi
approv
committe
ethic
anim
welfar
faculti
veterinari
medicin
technic
univers
lisbon
cebea
clinic
improv
evalu
use
scorescal
gil
et
al
includ
import
paramet
associ
retrovir
infect
name
oral
ulcersging
score
caudal
stomatitispalat
score
ophthalm
abnorm
score
lymphadenopathi
score
ocular
nasal
discharg
score
mucou
membran
color
score
coat
appear
score
bodi
score
score
faecal
appear
score
concurr
diseasescomorbid
score
time
point
total
score
cat
obtain
sum
correspond
clinic
score
overal
score
compar
studi
period
clinic
improv
classifi
mark
improv
initi
score
mild
improv
stabl
final
initi
score
wors
final
score
elev
initi
oral
rectal
swab
collect
time
point
assess
potenti
variat
concurr
excret
herpesviru
caliciviru
fcv
coronaviru
fcov
parvoviru
fpv
swab
process
viral
dnarna
extract
qiaamp
minelut
viru
spin
kit
qiagen
portug
determin
quantif
concurr
viral
excret
perform
use
diagnost
procedur
avail
virolog
laboratori
faculti
veterinari
medicin
technic
univers
lisbon
detail
screen
quantif
fcov
perform
realtim
polymeras
chain
reaction
pcr
fcv
presenc
assess
convent
revers
transcriptas
pcr
methodolog
use
previous
publish
gil
et
al
due
technic
updat
fpv
also
assess
realtim
pcr
po
group
fpv
primer
taqman
probe
calcul
use
primer
design
tool
ncbi
http
wwwncbinlmnihgovtoolsprimerblast
base
nucleotid
sequenc
gene
screen
quantif
fpv
assess
real
time
polymeras
chain
reaction
pcr
amplif
appli
instrument
appli
biosystem
reaction
use
taqman
gene
express
master
mix
appli
biosystem
lm
forward
primer
lm
revers
primer
lm
taqman
probe
fam
tamra
ng
templat
cycl
condit
compris
initi
denatur
step
min
follow
cycl
min
estim
fpv
copi
number
serial
tenfold
dilut
recombin
plasmid
dna
use
gener
standard
curv
correl
effici
r
use
system
sd
softwar
blood
sampl
collect
jugular
venipunctur
clinic
evalu
complet
bloodcel
count
cbc
hepat
enzym
alaninetransaminas
aspartatetransaminas
renal
function
serum
creatinin
urea
assess
cbc
biochemistri
perform
respect
celldyn
abbott
diagnost
divis
kone
optima
kemia
cientifica
saa
crp
measur
elisa
use
previous
valid
kit
phase
saa
multispeciestridelta
cat
crp
elisa
kamiya
biomed
compani
respect
agp
assess
singl
radial
immunodiffus
felin
agp
srid
tridelta
measur
perform
accord
manufactur
instruct
clinic
immunolog
paramet
interest
two
group
compar
begin
end
therapi
use
mannwhitneywilcoxon
test
independ
sampl
group
comparison
measur
begin
end
therapi
also
carri
mannwhitneywilcoxon
test
pair
sampl
test
use
version
small
sampl
size
eg
continu
correct
signific
level
fix
po
group
present
simpl
descript
statist
analysi
indoor
outdoor
cat
appropri
due
small
size
also
concurr
viral
excret
result
margin
due
low
initi
excret
rate
descript
statist
analysi
present
calcul
undertaken
r
statist
softwar
version
wwwrprojectorg
regard
clinic
score
group
indistinguish
begin
end
therapi
p
respect
although
signific
po
group
reveal
overal
higher
clinic
score
sc
one
regard
clinic
improv
sc
group
cat
improv
overal
score
p
particular
mark
improv
mild
improv
remain
stabl
worsen
observ
oral
lesion
common
clinic
sign
individu
clinic
score
cat
end
therapi
present
fig
po
group
treat
cat
significantli
improv
overal
score
therapi
p
specif
treat
cat
show
mark
improv
reveal
mild
improv
remain
stabl
similarli
sc
group
worsen
observ
individu
clinic
score
cat
end
therapi
present
fig
although
anim
display
clinic
sign
overal
rapid
improv
cat
observ
begin
studi
day
onset
oral
therapi
signific
reduct
overal
clinic
score
homogen
drop
end
studi
data
shown
mild
increas
overal
clinic
score
observ
day
day
due
specif
worsen
episod
oral
granuloma
one
cat
ocular
nasal
discharg
anoth
one
data
shown
signific
clinic
paramet
affect
oral
lesion
oral
ulcer
caudal
stomat
ocular
discharg
except
ocular
nasal
discharg
show
slight
fluctuat
therapi
paramet
reveal
homogen
improv
data
shown
coat
appear
bodi
condit
score
ocular
discharg
clinic
paramet
show
remark
improv
statist
differ
group
proport
cat
show
improv
pearson
chisquar
test
yate
continu
correct
small
sampl
size
p
moreov
also
differ
grade
clinic
improv
mild
mark
group
pearson
chisquar
test
p
overal
result
group
present
tabl
po
group
concurr
viral
excret
minor
none
cat
posit
begin
therapi
occasion
excret
detect
consid
clinic
irrelev
end
therapi
cat
neg
indoor
outdoor
cat
show
limit
initi
excret
fpv
becam
neg
also
cat
indoor
outdoor
residu
excret
fcov
despit
fluctuat
therapi
two
becam
neg
one
increas
viral
excret
two
reduc
outdoor
indoor
cat
posit
caliciviru
retain
statu
throughout
therapi
one
indoor
cat
neg
becam
posit
end
therapi
opposit
previous
publish
sc
group
reveal
signific
reduct
concurr
viral
excret
gil
et
al
concern
cbc
result
cat
indoor
outdoor
cat
po
group
reveal
mild
moder
leucopenia
outdoor
cat
slightli
anem
indoor
outdoor
cat
show
clinic
unremark
erythrocytosi
clinic
compat
mild
subclin
dehydr
therapi
leucopen
cat
normal
leucocyt
count
one
cat
still
persist
mild
leucopenia
end
therapi
despit
improv
leucocyt
count
redblood
cell
count
slightli
anem
cat
fluctuat
therapi
end
protocol
hematocrit
one
cat
normal
whilst
worsen
reveal
moder
nonregen
normocyt
normochrom
anemia
differenti
leukogram
po
group
cat
remain
stabl
unremark
therapi
urea
creatinin
serum
level
remain
within
refer
interv
therapi
regard
hepat
transaminas
outdoor
cat
mild
moder
increas
alt
ast
one
normal
remain
within
refer
interv
end
studi
wherea
persist
longer
normal
signific
chang
spe
detect
either
group
therapi
fig
group
initi
present
pattern
increas
total
protein
hypergammaglobulinemia
also
group
albumin
within
normal
rang
studi
despit
non
statist
signific
po
group
experienc
slight
decreas
total
protein
sc
group
increas
paramet
convers
hypergammaglobulinemia
remain
stabl
po
group
whilst
sc
group
increas
therapi
consid
environ
cat
indooroutdoor
submit
po
protocol
outdoor
cat
overal
higher
valu
gammaglobulin
total
protein
indoor
one
therapi
regard
app
profil
po
group
show
signific
higher
serum
level
agp
crp
saa
sc
one
p
respect
detail
baselin
valu
agp
crp
saa
po
group
respect
three
nine
seven
time
higher
sc
one
result
shown
tabl
previous
publish
app
level
increas
anim
treat
sc
protocol
leal
et
al
contrast
cat
treat
po
protocol
demonstr
signific
chang
app
serum
level
therapi
p
crp
saa
agp
respect
studi
show
independ
protocol
appli
rfeifnx
induc
signific
clinic
improv
treat
fivinfect
cat
unexpectedli
although
statist
signific
po
group
slightli
higher
overal
clinic
score
sc
group
due
fact
five
outdoor
cat
reveal
higher
clinic
score
cat
sc
group
counterbalanc
almost
asymptomat
indoor
cat
fact
signific
differ
observ
clinic
improv
group
suggest
clinic
set
cost
might
limit
factor
subcutan
administr
might
problemat
rfeifnx
may
administ
oral
success
fiv
posit
cat
howev
despit
lack
statist
differ
rfeifnx
licens
protocol
subcutan
inject
appear
induc
mark
clinic
improv
larger
proport
cat
gil
et
al
suggest
licens
protocol
seem
better
choic
symptomat
cat
effect
mark
clinic
improv
desir
felin
recombin
product
induc
neutral
antibodi
mean
highdos
protocol
may
use
safe
effici
even
repeat
administr
requir
import
factor
consid
condit
manag
lifelong
expect
concurr
viral
excret
minim
po
group
mainli
due
fact
anim
live
shelter
condit
opportunist
infect
difficult
control
despit
appar
overal
reduct
viral
load
fcov
fpv
oral
treatment
find
consid
without
clinic
signific
take
account
low
initi
viral
load
group
studi
requir
fulli
clarifi
role
oral
rfeifnx
reduct
concurr
viral
excret
particularli
shelter
medicin
regard
caliciviru
statu
chang
observ
posit
anim
oral
treatment
one
neg
cat
becam
posit
therapi
relationship
clinic
present
oral
rfeifnx
induc
use
clinic
improv
anim
spite
fact
remain
fcv
posit
agre
previou
studi
describ
longterm
carrier
state
mani
cat
coyn
et
al
accord
author
truli
persist
infect
rel
rare
fcvposit
cat
undergo
cyclic
reinfect
result
oral
group
also
somewhat
contrast
group
receiv
higher
dose
subcutan
inject
reduct
viral
excret
mark
nevertheless
studi
reveal
benefici
immunemodul
obtain
even
low
oral
dose
rfeifnx
similar
fashion
hifna
tompkin
may
induc
local
stimul
lymphoid
tissu
result
system
modul
immun
respons
studi
regard
rfeifnx
pharmacokinet
scarc
ueda
et
al
contrast
hifna
author
report
rfeifnx
acid
resist
mean
may
greater
rel
oral
absorpt
activ
gutassoci
lymphoid
tissu
thu
better
potenti
overal
immun
system
addi
ueda
et
al
contrast
licens
protocol
gil
et
al
po
protocol
use
improv
oral
lesion
ulcer
caudal
stomat
milder
contrast
effect
seen
previou
studi
oral
administr
protocol
induc
signific
improv
cat
refractori
caudal
stomat
hennet
et
al
one
major
differ
studi
cat
retroviru
neg
suggest
treat
retroviru
posit
cat
caudal
stomat
better
result
may
obtain
protocol
least
initi
use
higher
inject
dose
despit
limit
impact
caudal
stomat
viral
excret
oral
protocol
result
signific
improv
paramet
bodi
condit
coat
appear
coat
appear
non
specif
sign
cat
author
opinion
good
esthet
improv
anim
might
favor
point
improv
owner
complianc
regard
bodi
condit
previous
report
rfeifnx
may
help
initi
resolut
anorexia
hypertherm
cat
lutz
et
al
although
anorexia
report
studi
anim
increas
weight
agreement
previous
cite
trial
use
oral
rfeifnx
fivposit
asymptomat
cat
caney
et
al
particularli
import
thin
debilit
anim
also
describ
author
hennet
et
al
clinic
improv
observ
may
relat
relief
oral
lesion
even
mild
help
improv
mastic
increas
appetit
anim
ocular
discharg
also
show
good
improv
probabl
relat
control
opportunist
infect
subsequ
immun
modul
rather
direct
local
antivir
effect
regard
hematolog
biochemistri
despit
mild
fluctuat
signific
chang
observ
either
group
unremark
erythrocytosi
observ
cat
po
group
clinic
compat
mild
subclin
dehydr
cat
develop
moder
nonregen
normocit
mean
valu
standard
error
serum
amyloid
saa
agp
creactiv
protein
crp
serum
level
fiv
posit
cat
therapi
licens
rfeifnx
sc
group
oral
po
group
protocol
saa
lgml
agp
lgml
crp
lgml
normochrom
anemia
submit
clinic
workup
anemia
consid
result
chronic
inflamm
concurr
respiratori
tract
diseas
end
studi
anim
treat
antibiot
cefovecin
improv
respect
blood
result
consid
two
outdoor
cat
po
group
reveal
transitori
elev
alt
ast
serum
level
possibl
hepat
lipidosi
secondari
inappropri
food
intak
subclin
pancreat
consid
howev
recogn
anim
show
clinic
abnorm
increas
analyt
valu
normal
within
period
studi
owner
refus
perform
respect
complementari
exam
suggest
similarli
licens
protocol
expect
oral
rfeifnx
induc
signific
hematolog
biochem
chang
spe
result
show
anim
group
present
hypergammaglobulinemia
concurr
hyperproteinemia
begin
studi
find
corrobor
result
previou
studi
describ
hypergammaglobulinemia
fiv
posit
cat
due
concurr
opportunist
infect
polyclon
bcell
activ
gleich
hartmann
hartmann
consid
signific
chang
observ
either
group
rfeifnx
seem
interfer
spe
independ
protocol
administ
howev
despit
lack
statist
signific
appear
tendenc
hypergammaglobulinemia
increas
sc
group
concurr
viral
excret
reduc
gil
et
al
suggest
could
relat
subtl
detect
immun
stimul
increas
activ
bcell
contrast
observ
po
group
hypergammaglobulinemia
total
protein
remain
stabl
therapi
expect
outdoor
cat
show
evid
hypergammaglobulinemia
rais
total
protein
level
indoor
one
could
simpli
relat
higher
level
antigenexposur
differ
environ
consid
app
profil
po
group
reveal
higher
agp
saa
crp
serum
level
compar
sc
one
previou
result
describ
increas
app
level
fivposit
cat
treat
sc
protocol
leal
et
al
contrast
administr
oral
rfeifnx
induc
signific
chang
crp
saa
agp
serum
level
agreement
previou
studi
perform
dog
app
higher
dog
privat
household
comparison
clean
kennel
yamamoto
et
al
thu
one
possibl
explan
reli
wide
exposur
differ
environment
factor
although
live
shelter
cat
sc
group
remain
restrict
particular
area
whilst
cat
po
group
even
indoor
one
probabl
contact
larger
varieti
differ
daili
stimuli
howev
argument
support
theori
fact
cat
anim
shelter
posit
concurr
virus
gil
et
al
suggest
environment
factor
less
control
group
subsequ
cat
improv
clinic
condit
rfeifnx
therapi
app
level
increas
concurr
viral
excret
decreas
therefor
simpli
environment
exposur
pathogen
data
support
hypothesi
shelter
cat
evid
immunesuppress
basal
health
statu
explain
poor
innat
respons
subsequ
lower
level
app
despit
clear
evid
opportunist
infect
consequ
shelterh
sc
group
show
lower
initi
level
app
increas
therapi
suggest
restor
immun
compet
oral
rfeifnx
significantli
chang
app
profil
mean
despit
chronic
oral
therapi
observ
clinic
benefit
seem
relat
increas
app
profil
anim
suggest
explan
reli
fact
chronic
oral
therapi
may
induc
overal
clinic
improv
due
local
action
directli
mucosa
local
lymphoid
area
potenti
local
immun
respons
rather
system
one
therefor
sc
protocol
base
pulsat
cycl
higher
dose
rfeifnx
seem
relev
system
role
potenti
innat
immun
oral
protocol
suggest
act
differ
direct
local
immun
respons
consid
higher
initi
app
level
po
group
studi
alon
suffici
determin
whether
licens
protocol
potent
potenti
innateimmun
respons
simpli
impact
factor
live
environ
better
initi
immun
compet
studi
name
evalu
cytokin
profil
express
name
proinflammatori
one
tumor
necrosi
factor
relat
app
profil
would
clarifi
major
differ
group
limit
studi
use
cat
live
differ
environ
seem
reason
assum
anim
shelter
tend
expos
condit
higher
morbid
hous
cat
therefor
mark
clinic
improv
may
like
immunemodul
therapi
perform
howev
recogn
protocol
differ
durat
rout
administr
blind
studi
seem
unreason
simpli
compar
protocol
studi
allow
us
assess
clinic
improv
cat
individu
baselin
data
cat
also
provid
use
compar
inform
despit
heterogen
environ
initi
clinic
score
differ
group
made
sc
group
reliabl
posit
control
clinic
improv
assess
furthermor
rfeifnx
treat
fivinfect
cat
previous
studi
singlearm
trial
permit
reduct
number
anim
use
research
howev
paramet
name
app
differ
group
signific
reflect
differ
basal
immun
statu
rather
household
cat
seem
reason
assum
cat
anim
shelter
live
catteri
differ
extrins
factor
affect
immun
respons
therefor
particularli
paramet
posit
group
control
less
reliabl
even
though
app
intrins
variabl
even
healthi
cat
reason
recommend
anim
act
refer
ceron
et
al
compar
group
studi
evalu
app
tendenc
oral
protocol
baselin
valu
intrins
refer
analysi
minim
initi
discrep
observ
group
first
studi
describ
success
applic
oral
rfeifnx
protocol
symptomat
fivinfect
cat
open
new
insight
detail
immunolog
studi
highli
probabl
licens
protocol
provid
suffici
level
interferon
system
induc
direct
antivir
stimulu
contrast
oral
protocol
system
absorpt
rel
limit
dose
use
also
significantli
lower
may
explain
appar
greater
benefit
inject
protocol
cat
initi
higher
clinic
score
cat
high
initi
level
viru
shed
suggest
taken
account
choos
protocol
individu
cat
clinic
set
although
laboratori
chang
subtler
observ
sc
protocol
oral
rfeifnx
nevertheless
result
use
improv
anim
condit
consid
significantli
reduc
cost
product
could
interest
altern
immunemodul
therapi
fivinfect
cat
mild
moder
clinic
present
current
licens
protocol
difficult
perform
addit
may
interest
option
treatment
followup
licens
protocol
condit
cat
better
stabil
secondari
viral
infect
better
control
